UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
July 12, 2018
Date of Report (Date of earliest event reported)
HELIUS MEDICAL TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
|
WYOMING |
001-38445 |
36-4787690 |
|
(State or other jurisdiction of |
(Commission |
(I.R.S. Employer |
|
incorporation or organization) |
File Number) |
Identification No.) |
(Exact name of registrant as specified in charter)
642 Newtown Yardley Road, Suite 100
Newtown, Pennsylvania, 18940
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (215) 944-6100
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting material pursuant to Rule 14a12 under the Exchange Act (17 CFR 240.14a12) |
|
|
☐ |
Precommencement communications pursuant to Rule 14d2(b) under the Exchange Act (17 CFR 240.14d2(b)) |
|
|
☐ |
Precommencement communications pursuant to Rule 13e4(c) under the Exchange Act (17 CFR 240.13e4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b‑2 of the Securities Exchange Act of 1934 (§240.12b‑2 of this chapter).
Emerging growth company ☑
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☑
|
Item 7.01 |
Regulation FD Disclosure
|
On July 12, 2018, Helius Medical Technologies, Inc. (the “Company”) issued a press release announcing the appointment of Jennifer Laux as the Company’s Chief Commercialization Officer. A copy of the press release is furnished herewith as Exhibit 99.1.
The information set forth in this Item 7.01 and in the press release attached hereto as Exhibit 99.1, is deemed to be “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except to the extent that the Company specifically incorporates it by reference.
Item 9.01.Financial Statements and Exhibits.
(d) Exhibits
|
|
Exhibit |
|
|
||
|
|
Number |
|
Exhibit Description |
||
|
99.1 |
|
||||
2
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
HELIUS MEDICAL TECHNOLOGIES, INC. |
|
|
|
|
|
|
Dated: July 12, 2018 |
By: |
/s/ Joyce LaViscount |
|
|
|
Joyce LaViscount, Chief Financial Officer |
|
|
|
|
3
Helius Medical Technologies, Inc. Names Jennifer Laux as Chief Commercialization Officer
NEWTOWN, Pa., July 12, 2018 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, is pleased to announce the appointment of Jennifer Laux as Chief Commercialization Officer, effective July 9, 2018.
“We are delighted to have someone with Jennifer’s exceptional skills and experience in this role,” said Helius’ CEO, Philippe Deschamps. “Her experience growing commercial organizations and bringing global products to market will be invaluable as Helius enters its next stage of growth.”
”I’m thrilled to join the Helius team, as we prepare to commercialize the company’s innovative PoNSTM technology, for the treatment of chronic balance disorders associated with mild to moderate traumatic brain injury,” said Ms. Laux. “Helius is positioning itself to serve this large, high unmet needs market and continue to develop its innovative technology, with the goal of addressing the symptoms of other neurological diseases or trauma.”
Ms. Laux brings extensive experience in leading successful global commercialization strategies and new product launches. Prior to joining Helius, Ms. Laux was Vice President at Inovio Pharmaceuticals, Inc., where she headed commercial, launch, and new product strategy and was instrumental in prioritizing the portfolio of commercial assets and developing the go-to-market strategy for the company’s lead asset. Before joining Inovio, Ms. Laux was Vice-President of marketing at Boehringer Ingelheim, where she directed strategy execution, brand planning, and sales for the company’s cardiovascular franchise. Prior to this, Ms. Laux served for 17 years at Merck & Co., Inc., where she held numerous marketing leadership positions in Merck’s cardiovascular, oncology, women’s health, and specialty franchises.
Ms. Laux earned a B.A. in International Studies and English from Georgetown University and an M.B.A. and M.A. in Marketing and International Studies from the Wharton School and Joseph H. Lauder Institute at the University of Pennsylvania.
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company’s first product in development is the Portable Neuromodulation Stimulator (PoNSTM). For more information, visit www.heliusmedical.com.
About the PoNS Device and PoNS Treatment
The Portable Neuromodulation Stimulator (PoNS) is an investigational, non-invasive, medical device.
PoNS Treatment is the first and only tongue-delivered neuromodulation that combines stimulation of cranial nerves with physical and cognitive therapy to restore lost neurological function. The Company’s trials investigating the PoNS in traumatic brain injury are more fully discussed in the Company’s disclosure materials, including its Annual Report on Form 10-K and other filings with the United States Securities and Exchange Commission and the Canadian securities regulators and which can be obtained from either at www.sec.gov or www.sedar.com.
Cautionary Disclaimer Statement:
Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws.
All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Such forward-looking statements include, among others, the company’s future operations, including future regulatory submissions and approvals or other business initiatives and objectives.
Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects”, “estimate”, “intend” and similar expressions.
There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the Company’s need to raise additional capital to achieve its business objectives and other risks detailed from time to time in the filings made by the Company with securities regulators.
The reader is cautioned that assumptions used in the preparation of any forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking
statement. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. Risks and uncertainties about the Company’s business are more fully discussed in the Company’s disclosure materials, including its Annual Report on Form 10-K and other filings with the United States Securities and Exchange Commission and the Canadian securities regulators and which can be obtained from either at www.sec.gov or www.sedar.com.
The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law.
The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
Investor Relations Contact:
Westwicke Partners on behalf of Helius Medical Technologies, Inc.
Mike Piccinino, CFA
443-213-0500
info@heliusmedical.com